Successful treatment of acute myeloid leukemia co-expressing NUP98/NSD1 and FLT3/ITD with preemptive donor lymphocyte infusions.
We report a refractory case of molecular relapse of AML co-expressing NUP98/NSD1 and FLT3/ITD post-matched sibling HSCT. Donor lymphocyte infusion (DLI) at an early stage of post-transplantation resulted in complete molecular remission for 29 months with durable chronic graft-versus-host disease. Our case suggests the clinical efficacy of preemptive DLI following minimal residual disease analysis for the treatment of refractory AML.
PMID: 31134509 [PubMed - as supplied by publisher]
Source: International Journal of Hematology - Category: Hematology Authors: Mitani Y, Hiwatari M, Seki M, Hangai M, Takita J Tags: Int J Hematol Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Chronic Leukemia | Hematology | Leukemia | Stem Cell Therapy | Stem Cells | Study | Transplants